Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

Overview

Journal Int J Angiol

Date 2023 Aug 14

PMID 37576533

Authors

Hussam A S Murad

Marwan A Bakarman

Affiliations

Soon will be listed here.

Abstract

Plasma level of chemokine CXCL12 can predict adverse cardiovascular outcomes in patients with coronary artery disease, but data on its relationship with severity of coronary stenosis in cases of severe myocardial infarction (MI) are scarce and conflicting. The objective of this study was to investigate link between plasma CXCL12 levels and different grades of left ventricular ejection fraction (LVEF) in statin-treated and -untreated patients with severe MI. A total of 198 consecutive patients with first-time severe MI (ST-elevated myocardial infarction [STEMI], = 121 and non-ST-elevated myocardial infarction [NSTEMI], = 77) were recruited from Coronary Care Unit, King Abdulaziz University Hospital. They have one to two coronary arteries blocked ≥50%, or three arteries blocked 30 to 49%. Demographic and clinical criteria were collected and plasma CXCL12 level was measured. No correlations were detected between demographic and clinical criteria and CXCL12 level. While troponin peaks and LVEF significantly differed between STEMI and NSTEMI patients, CXCL12 level showed nonsignificant changes. Plasma CXCL12 levels decreased significantly in statin-treated patients compared with those untreated. From receiver operating characteristic (ROC) analysis, high CXCL12 levels were associated with no statin therapy. For STEMI and NSTEMI patients, area under the receiver operating characteristic curve for CXCL12 test were 0.685 and 0.820, while sensitivity and specificity values were 75.9 and 54.8%, and 73.1 and 84%, respectively. Plasma CXCL12 levels showed nonsignificant changes with different ranges of LVEF and troponin peaks. In patients with severe MI, irrespective of statin therapy, plasma CXCL12 showed no correlation with different ranges of LVEF suggesting that it cannot predict left ventricular dysfunction in these cases. However, cross-sectional design of this study is a limitation.

References

Jiangping S, Zhe Z, Wei W, Yunhu S, Jie H, Hongyue W . Assessment of coronary artery stenosis by coronary angiography: a head-to-head comparison with pathological coronary artery anatomy. Circ Cardiovasc Interv. 2013; 6(3):262-8. DOI: 10.1161/CIRCINTERVENTIONS.112.000205. View

Ostadal P . Statins as first-line therapy for acute coronary syndrome?. Exp Clin Cardiol. 2013; 17(4):227-36. PMC: 3627281. View

Ferdousie V, Mohammadi M, Hassanshahi G, Khorramdelazad H, Khanamani Falahati-Pour S, Mirzaei M . Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion. Int J Cardiol. 2017; 233:23-28. DOI: 10.1016/j.ijcard.2017.02.011. View

SCANLON P, Faxon D, Audet A, Carabello B, Dehmer G, Eagle K . ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in.... Circulation. 1999; 99(17):2345-57. DOI: 10.1161/01.cir.99.17.2345. View

Mehta N, Li M, William D, Khera A, DerOhannessian S, Qu L . The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. Eur Heart J. 2011; 32(8):963-71. PMC: 3076669. DOI: 10.1093/eurheartj/ehr091. View

Yu S, Jin J, Chen Z, Luo X . High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020; 19(1):194. PMC: 7444068. DOI: 10.1186/s12944-020-01369-6. View

Arnold S, Spertus J, Tang F, Krumholz H, Borden W, Farmer S . Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011; 124(22):2405-10. PMC: 3527107. DOI: 10.1161/CIRCULATIONAHA.111.038265. View

Mahajan V, Jarolim P . How to interpret elevated cardiac troponin levels. Circulation. 2011; 124(21):2350-4. DOI: 10.1161/CIRCULATIONAHA.111.023697. View

Timotijevic G, Mostarica Stojkovic M, Miljkovic D . CXCL12: role in neuroinflammation. Int J Biochem Cell Biol. 2012; 44(6):838-41. DOI: 10.1016/j.biocel.2012.03.014. View

10.

Cummins B, Auckland M, Cummins P . Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J. 1987; 113(6):1333-44. DOI: 10.1016/0002-8703(87)90645-4. View

11.

Bodi V, Nunez J, Sanchis J, Llacer A, Facila L, Chorro F . [Usefulness of troponin I for predicting systolic dysfunction in acute coronary syndromes. Results of a prospective and quantitative study]. Rev Esp Cardiol. 2003; 56(7):738-41. DOI: 10.1016/s0300-8932(03)76946-2. View

12.

Keeley E, Moorman J, Liu L, Gimple L, Lipson L, Ragosta M . Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One. 2011; 6(6):e21174. PMC: 3120847. DOI: 10.1371/journal.pone.0021174. View

13.

Chen J, Chemaly E, Liang L, Kho C, Lee A, Park J . Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol. 2010; 176(4):1705-15. PMC: 2843462. DOI: 10.2353/ajpath.2010.090451. View

14.

Chatterjee M . Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology. Cells. 2022; 11(2). PMC: 8773869. DOI: 10.3390/cells11020213. View

15.

Apple F, Ler R, Murakami M . Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem. 2012; 58(11):1574-81. DOI: 10.1373/clinchem.2012.192716. View

16.

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

17.

Kim C, Choi D . Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?. J Thorac Dis. 2018; 10(Suppl 18):S2149-S2152. PMC: 6072956. DOI: 10.21037/jtd.2018.06.46. View

18.

Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C . Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017; 135(13):1253-1264. DOI: 10.1161/CIRCULATIONAHA.116.023027. View

19.

Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N . MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol. 2014; 192(11):5273-84. DOI: 10.4049/jimmunol.1302209. View

20.

Ghasemzadeh N, Hritani A, De Staercke C, Eapen D, Veledar E, Al Kassem H . Plasma stromal cell-derived factor 1α/CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease. Atherosclerosis. 2014; 238(1):113-8. PMC: 4721225. DOI: 10.1016/j.atherosclerosis.2014.10.094. View